2,368 patients who underwent complete resection of CLM at Memorial Sloan Kettering were consecutively enrolled in a prospectively maintained database.

• Patients who received the Intera 3000 plus systemic chemotherapy had a median overall survival of 67 months. Patients who received systemic chemotherapy alone had a median survival of 47 months (P<0.001).
• In propensity score analysis, the same strong association with overall survival was found with an adjusted hazard ratio for HAI of 0.67 (P < 0.001).
• Patients who received the Intera 3000 plus systemic chemotherapy had overall survival of 52.9% at 5 years versus overall survival of 37.9% with systemic chemotherapy alone (P<0.001). 
• Patients who received the Intera 3000 plus systemic chemotherapy had overall survival of 38.0% at 10 years versus overall survival of 23.8% with systemic chemotherapy alone (P<0.001).
• Use of the Intera 3000 was not associated with increased overall survival in patients with extrahepatic disease, a positive resection margin, or a clinical risk score of 4 or 5. Overall survival for patients in this study who did not receive the Intera 3000 was similar to overall survival in other large studies without the Intera 3000.